Business

Strides’ subsidiary inks pact with SUDA Pharmaceuticals for migraine drug

Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug thumbnail

Under the terms of agreement, SUDA will receive an upfront cash payment of USD 0.4 million and a further payment of USD 0.6 million on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the U…

Under the terms of agreement, SUDA will receive an upfront cash payment of USD 0.4 million and a further payment of USD 0.6 million on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the U…
Read More

Leave a Comment